

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10EV 731062888 US
Express Mail Label NumberNovember 8, 2005
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

LANE ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/08719

FILED: 6 AUGUST 2003

U.S. APPLICATION NO: 10/523,047

35 USC §371 DATE: 2 FEBRUARY 2005

FOR: METHODS FOR THE TREATMENT OF DEMENTIA BASED ON
APO E GENOTYPE**MS: Amendment**Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits. Under 37 C.F.R. §1.97(b)(3), no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/08719, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3346



John T. Prince
Attorney for Applicants
Reg. No. 43,019

Date: November 8, 2005

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-32609A
APPLICATION NO.
10/523,047
APPLICANT
LANE ET AL.
FILING DATE
FEBRUARY 2, 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,391,553	5/02	Amouyel, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 95/16791	6/95	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	
	AS	
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-32609A
APPLICATION NO.
10/523,047
APPLICANT
LANE ET AL.
FILING DATE
FEBRUARY 2, 2005

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Winblad, et al., "A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD", Neurology, Vol. 57, pp. 489-95 (2001)
DB	Farlow et al., "Apolipoprotein E genotype and gender influence response to tacrine therapy", Annals of the New York Academy of Sciences; Apolipoprotein E, pp. 101-110, (1996)
DC	Sjogren et al., "Tacrine and rate of progression in Alzheimer's disease: relation to ApoE allele genotype", Journal of Neural Transmission, Vol. 108, pp. 451-58, (2001)
DD	Aerssens et al., "ApoE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease," Dementia and Geriatric Cognitive Disorders, Vol. 12, pp. 69-77, (2001)
DE	Nobili et al., "Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors," Journal of Nuclear Medicine, Vol. 43, pp. 983-90, (2002)
DF	Database WPI, Derwent Publications Ltd., London, GB; An 2000-264443, XP002265851, "Apolipoprotein E4-specific monoclonal antibody used for immunoassay of ApoE does not react with ApoE isoforms 2 and 3," (March 2000)
DG	Stefanova et al., "Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients." Neuroscience Letters, Ireland, Vol. 338, pp. 159-163, (2003)
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.